Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12081097rdf:typepubmed:Citationlld:pubmed
pubmed-article:12081097lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:12081097lifeskim:mentionsumls-concept:C0376574lld:lifeskim
pubmed-article:12081097lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:12081097lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:12081097lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12081097lifeskim:mentionsumls-concept:C0022277lld:lifeskim
pubmed-article:12081097lifeskim:mentionsumls-concept:C1710133lld:lifeskim
pubmed-article:12081097pubmed:issue9lld:pubmed
pubmed-article:12081097pubmed:dateCreated2002-6-25lld:pubmed
pubmed-article:12081097pubmed:abstractTextFlaviviridae-hepatitis C virus (HCV) and GB virus C/hepatitis G virus (GBV-C/HGV)--and human immunodeficiency virus (HIV) frequently show similar modes of transmission. HCV and GBV-C/HGV infection was assessed in 134 consecutive patients with evidence of HIV infection, living in Campania, Italy. Data obtained from this cohort were compared with those obtained from 252 age- and sex-matched HCV infected patients without evidence of HIV infection (HCV control group). Following enzymatic immunoassays, samples were tested for the presence of HCV-RNA by RT-PCR. The HCV-RNA positive sera were genotyped by LiPA procedure. The prevalence of HCV infection in HIV patients was 19.40% and the largest group of HIV-HCV co-infected patients (84.62%) was represented by intravenous drug users (IVDU). The distribution of HCV genotypes in HIV-HCV patients was different, compared to that observed in HCV control group. HCV genotypes la (50%) and 3a (23.08%) were more frequently detected in HIV HCV patients, compared to HCV control group (5.16 and 5.56% for la and 3a, respectively). Conversely, HCV genotypes lb (55.70%) and 2a/2c (30.26%) were more represented in HCV control group, compared to HIV-HCV patients (15.38 and 0% for lb and 2a/2c, respectively). GBV-C/HGV seroprevalence was 41.04% in HIV patients and 6.54% in healthy control individuals. Differently from HCV, GBV-C/HGV infection did not correlate to a preferential risk behaviour in the HIV cohort. Comparative analysis of HCV and GBV-C/HGV infection indicates that the use of injecting drugs might play a key role in the epidemiology of HCV and, in particular, of la and 3a HCV genotypes, in HIV patients.lld:pubmed
pubmed-article:12081097pubmed:languageenglld:pubmed
pubmed-article:12081097pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12081097pubmed:citationSubsetIMlld:pubmed
pubmed-article:12081097pubmed:statusMEDLINElld:pubmed
pubmed-article:12081097pubmed:issn0393-2990lld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:LaccettiPPlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:D'OnofrioMMlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:LiuzzoAAlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:BorgiaGGlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:FormisanoPPlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:PortellaGGlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:IuraAAlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:BonadiesGGlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:RendinaDDlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:VigoritaEElld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:BonavoltaRRlld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:PietronigroM...lld:pubmed
pubmed-article:12081097pubmed:authorpubmed-author:LaccettiRRlld:pubmed
pubmed-article:12081097pubmed:issnTypePrintlld:pubmed
pubmed-article:12081097pubmed:volume17lld:pubmed
pubmed-article:12081097pubmed:ownerNLMlld:pubmed
pubmed-article:12081097pubmed:authorsCompleteYlld:pubmed
pubmed-article:12081097pubmed:pagination801-7lld:pubmed
pubmed-article:12081097pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:meshHeadingpubmed-meshheading:12081097...lld:pubmed
pubmed-article:12081097pubmed:year2001lld:pubmed
pubmed-article:12081097pubmed:articleTitleHCV and GBV-c/HGV infection in HIV positive patients in southern Italy.lld:pubmed
pubmed-article:12081097pubmed:affiliationDipartimento Assistenziale di Patologia Clinica, Facoltà di Medicina e Chirurgia Università di Napoli Federico II, Italy.lld:pubmed
pubmed-article:12081097pubmed:publicationTypeJournal Articlelld:pubmed